公开(公告)号：US07807701B2

公开(公告)日：2010-10-05

申请号：US11939359

申请日：2007-11-13

申请人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

发明人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

IPC分类号： A61K31/41 ,  A61K31/42 ,  C07D257/04 ,  C07D263/30

CPC分类号： C07D213/74 ,  C07C229/46 ,  C07C255/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D231/38 ,  C07D239/42 ,  C07D249/14 ,  C07D257/06 ,  C07D261/14 ,  C07D263/48 ,  C07D271/07 ,  C07D271/10 ,  C07D275/02

摘要： A dibenzylamine compound represented by the formula (1) wherein R1 and R2 are each a C1-6 allyl group optionally substituted by halogen atoms and the like; R3, R4 and R5 are each a hydrogen atom, a halogen atom and the like, or R3 and R4 may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is —N(R7)(R8) and the like; ring B is an aryl group or a heterocyclic residue; R6 is a hydrogen atom, a halogen atom, a nitro group, a C1-6 allyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.

摘要翻译： 由式（1）表示的二苄胺化合物，其中R 1和R 2各自为任选被卤素原子等取代的C 1-6烯丙基; R 3，R 4和R 5各自为氢原子，卤素原子等，或者R 3和R 4可以与其键合的碳原子一起形成任选具有取代基的双环或杂环; A是-N（R 7）（R 8）等; 环B是芳基或杂环残基; R6是氢原子，卤素原子，硝基，C1-6烯丙基等; n为1〜3的整数，其前药及其药学上可接受的盐具有选择性且有效的CETP抑制活性，因此可作为高脂血症或动脉硬化等的治疗剂或预防剂使用。

公开(公告)号：US07332514B2

公开(公告)日：2008-02-19

申请号：US10503185

申请日：2003-08-29

申请人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

发明人： Kimiya Maeda ,  Hironobu Nagamori ,  Hiroshi Nakamura ,  Hisashi Shinkai ,  Yasunori Suzuki ,  Daisuke Takahashi ,  Toshio Taniguchi

IPC分类号： A61K31/42 ,  A61K31/41 ,  C07D263/30 ,  C07D257/04

CPC分类号： C07D213/74 ,  C07C229/46 ,  C07C255/58 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D231/38 ,  C07D239/42 ,  C07D249/14 ,  C07D257/06 ,  C07D261/14 ,  C07D263/48 ,  C07D271/07 ,  C07D271/10 ,  C07D275/02

摘要： A dibenzylamine compound represented by the formula (1) wherein R1 and R2 are each a C1-6 alkyl group optionally substituted by halogen atoms and the like; R3, R4 and R5 are each a hydrogen atom, a halogen atom and the like, or R3 and R4 may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is —N(R7) (R8) and the like; ring B is an aryl group or a heterocyclic residue; R6 is a hydrogen atom, a halogen atom, a nitro group, a C1-6 alkyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.

摘要翻译： 由式（1）表示的二苄胺化合物，其中R 1和R 2各自为任选被卤素取代的C 1-6烷基 原子等; R 3，R 4和R 5各自为氢原子，卤素原子等，或R 3， SUP>和R 4可以与其键合的碳原子一起形成任选具有取代基的杂环或杂环; A是-N（R 7）（R 8）等; 环B是芳基或杂环残基; R 6是氢原子，卤素原子，硝基，C 1-6烷基等; n为1〜3的整数，其前药及其药学上可接受的盐具有选择性且有效的CETP抑制活性，因此可作为高脂血症或动脉硬化等的治疗剂或预防剂使用。